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Abstract: Some previous reports have already shown the characterizations of immunomagnetic 
reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic 
nanoparticles to label target biomolecules. However, the detection threshold and interference 
tests for IMR have not been investigated in detail. In this study, alpha-fetoprotein (AFP) was 
used as a target biomolecule. The signals for AFP solutions of various concentrations, or with 
interfering materials, were detected via IMR. These samples were also used for characterizing 
the detection threshold and interference with enzyme-linked immunosorbent assay (ELISA). The 
results of assaying AFP level with IMR and ELISA were compared. The detection threshold for 
assaying AFP with IMR was found to be 3 ng/mL, which is 15 times lower than that of ELISA, 
and definitely suppresses false negative. For the interfering materials noted commonly in serum 
such as hemoglobin, bilirubin, triglyceride, and vascular endothelial growth factor, there was no 
detectable interfering effect when assaying AFP with IMR. Several serum samples from normal 
people and liver-tumor-bearing patients were used for the detections of AFP   concentration 
via IMR. These results reveal the feasibilities of assaying AFP in blood using IMR, as well as 
achieving high-sensitive and high-specific assay for AFP.
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Introduction
To improve the sensitivity and specificity of immunoassay, the developing trends are 
to lower the detection threshold and to minimize the cross reaction. Many research 
groups have improved in-use assay technologies.1–3 Some other groups have explored 
advanced technologies.4–7
Several years ago, some authors proposed an assay technology called 
  immunomagnetic reduction (IMR).5 In IMR, the reagent is a solution of homogeneously 
dispersed magnetic nanoparticles, which are coated with hydrophilic surfactants (eg, 
dextran) and bioprobes (eg, antibodies). Under external multiple alternating-current (ac) 
  magnetic fields, magnetic nanoparticles oscillate with the multiple ac magnetic fields 
via magnetic interaction (Figure 1A). Thus, the reagents under the external multiple 
ac magnetic fields show a magnetic property, called mixed-frequency ac magnetic 
susceptibility χac. With the bioprobes on the outmost shell, magnetic nanoparticles bind 
with and magnetically label the biomolecules (eg, target biomolecules) to be detected. 
Due to the binding, magnetic nanoparticles become larger or clustered (Figure 1B). 
The responses of these larger or clustered magnetic nanoparticles to external multiple 
ac magnetic fields are much less intense than those of the original individual magnetic 
nanoparticles. Thus, the χac of the reagent is reduced due to the binding between the 
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magnetic nanoparticles and target biomolecules. This is why 
the technology is referred to as immunomagnetic   reduction. 
In principle, when greater amounts of to-be-detected biomol-
ecules are mixed with a reagent, more magnetic nanoparticles 
become larger. Thus, a larger reduction in χac could be 
expected for the reagents.
To quantify the reduction in the χac due to the binding 
between magnetic nanoparticles and biomolecules, this report 
refers to χac as χac,o for the magnetic reagent without binding 
with the detected biomolecules, and as χac,φ for the magnetic 
reagent after the binding between magnetic nanoparticles and 
biomolecules. The reduction in χac hereafter is defined as:
  IMR (%) = (χac,o − χac,φ)/χac,φ × 100%  (1)
According to the description given above, IMR exhibits 
several unique merits. Firstly, it is not necessary to remove 
the unbound target biomolecules and magnetic nanoparticles. 
They are still in the reagent. Therefore, the assay process of 
IMR is simple. Secondly, only one kind of bioprobe is used. 
Thirdly, IMR is a direct and homogeneous assay, which 
  usually shows high reliability. Fourth, because the amount 
of reduction in χac can be accurately measured to correspond 
to the concentration of the to-be-detected biomolecules, the 
concentration of the biomolecules can thus be measured 
quantitatively.
Several papers have demonstrated that IMR can be 
applied to assay proteins,8 viruses,9 chemicals, and nucleic 
acids10 once suitable bioprobes are immobilized onto the 
magnetic nanoparticles. However, investigations of the 
detection threshold and interference tests of IMR have been 
very rare. Moreover, few studies have made comparisons 
between IMR and in-use assays. These uncertainties make 
it difficult to evaluate the accuracy or feasibilities of using 
IMR for clinic applications.
This study examined the detection threshold and interfer-
ence tests for IMR. Alpha-fetoprotein (AFP) was selected as 
the target biomolecule. To determine the detection thresh-
old for assaying AFP, the relationship between the AFP 
concentration and IMR (%) was built up experimentally. 
As to the interference tests, the contributions from the com-
monly existing biomolecules in human blood to IMR (%) 
were clarified. All these results were compared with those 
obtained with certificated assays in current practice, such as 
enzyme-linked immunosorbent assay (ELISA).
Materials and methods
The reagent for assaying AFP consists of magnetic 
  nanoparticles (MF-DEX-0060, MagQu, New Taipei, Taiwan, 
Republic of China) functionalized with antibodies (ab40942; 
Abcam, Cambridge, MA), against AFP (EA502-Q1053; 
EastCoast Bio, North Berwick, ME).11 The mean diameter 
of the antibody-functionalized magnetic nanoparticles is 
57.3 nm. These magnetic nanoparticles are dispersed in 
phosphoryl buffer solution (PBS). The concentration of the 
magnetic bioreagent is 1.2 mg-Fe/mL.
40-µL of magnetic bioreagent was mixed with 60 µL 
of sample solution in a glass tube. The mixed-frequency 
ac magnetic susceptibility χac of the mixture was detected 
as a function of time by using an IMR analyzer (XacPro-E; 
MagQu). The reduction percentage in χac, denoted as 
IMR (%), can be determined according to the time dependent 
χac of the mixture.
The commercial ELISA kit (AF064T; Calbiotech, Spring 
Valley, CA) for assaying AFP was used in this work. The 
optical density at the wavelength of 450 nm (OD450) was 
detected using an ELISA reader (Plus384; Spectra Max, 
Sunnyvale, CA). The procedures used for AFP assay fol-
lowed the protocols suggested by the commercial kits.
Various amounts of AFP were spiked into PBS for 
IMR assay. The concentrations of AFP solution varied from 
A χ
ac,o
B χ
ac,φ (<χac,o)
Figure  1  Illustration  of  mechanism  of  immunomagnetic  reduction  to  detect 
biotargets. (A) Each magnetic nanoparticle oscillates individually with the applied 
alternative-current magnetic field before binding with biotargets. (B) Portions of 
magnetic nanoparticles become larger due to the binding with biotargets. The bound 
magnetic nanoparticles in (B) contribute to the reduction in the alternative-current 
magnetic susceptibility of the reagent.
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0.1 ng/mL to 2000 ng/mL. These AFP solutions were used for 
establishing the AFP concentration-dependent IMR (%).
For interference tests, materials including hemoglobin 
(Hb) (H7379-1G; Sigma-Aldrich, St Louis, MO), conjugated 
bilirubin (C-BL) (14370-250MG; Sigma), triglyceride (TG) 
(T2449-10ML, Sigma), and vascular endothelial growth 
factor (VEGF) (sc-7269; Santa Cruz Biotechnology, Santa 
Cruz, CA), were mixed with AFP solutions, respectively. 
The concentrations of the interference materials used here 
are listed in Table 1. The related diseases and normal con-
centration levels for these interference materials were also 
tabulated. The IMR (%) for each sample with interference 
material was compared with that of pure AFP solution. For 
each sample, the IMR (%) was detected in triplicate.
Results and discussion
The experimental relationship between the IMR (%) and 
AFP concentration φAFP is shown with dots (Figure 2). The 
IMR (%) varies from 1.07% to 2.51% as φAFP increases from 
0.1 ng/mL to 2000 ng/mL. The dots in Figure 2 are fitted to 
the following logistic function:
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where A, B, φo, and γ are fitting parameters. These parameters 
are found as A = 1.13, B = 2.76, φo = 197.5, and γ = 0.78. 
The fitting curve is plotted with the solid line (Figure 2). The 
coefficient of determination, R2, between the dots and the 
fitting curve is 0.994.
These AFP solutions were also used for ELISA assay. 
The detected OD450 as a function of φAFP is shown with hollow 
squares (Figure 2). These hollow squares are guided with a 
dashed line. It is obvious that OD450 increases significantly 
as φAFP surpasses 50 ng/mL.
According to the dots (Figure 2), the IMR (%)–φAFP curve 
follows the logistic function, as expressed in   Equation (2). 
The fitting parameter A (= 1.13) in Equation (2) denotes 
the noise level for the IMR (%)–φAFP curve. The detection 
threshold in terms of the detected signal is   conventionally 
defined as that higher than the noise level with triple stan-
dard deviations for the detected signal at low   concentrations. 
In this work, the standard deviation of IMR (%) for 1 ng/mL 
is 0.02%. The detection threshold in terms of IMR (%) 
is 1.19%. Thus, the detection threshold in terms of AFP 
concentration φAFP can be determined via Equation (2), 
which results in 3.01 ng/mL. Obviously, the detection 
threshold is lowered by 15 times when using IMR instead 
of ELISA. The improvement in the detection threshold 
for IMR compared with ELISA is attributed from several 
  factors, such as antibodies, uniformity of magnetic particles, 
and the detecting modules for magnetic signals. From the 
assay system point of view, IMR definitely shows merits 
in terms of the detection threshold.
In practice, the reference criteria of the AFP serum level 
for diagnosis of hepatocellular carcinoma (HCC) are above 
20 ng/mL. According to the results (Figure 2), IMR shows 
the detection threshold of 3.01 ng/mL, which is much lower 
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Figure 2 AFP concentration-dependent IMR (%) (solid circles with the solid line) 
and  OD450  (open  squares  with  the  dashed  line)  obtained  with  IMR  and  ELISA, 
respectively.
Note: Points represent mean ± standard deviation.
Abbreviations: AFP, alphafetaprotein; IMR, immunomagnetic reduction; ELISA, 
enzyme-linked immunosorbent assay; OD, optical density.
Table 1 Information on interference materials used for the IMR and ELISA interference tests in this work
Interfering material Related disease Normal reference level Concentration used
Hemoglobin Hemolysis ,500 µg/mL 600 µg/mL 
1000 µg/mL
Conjugated bilirubin Jaundice ,2 µg/mL 5 µg/mL 
10 µg/mL
Triglyceride Hypertriglyceridemia 500–1500 µg/mL 2000 µg/mL
Vascular endothelial growth factor Malignancy ,0.05 ng/mL 0.1 ng/mL
Abbreviations: IMR, immunomagnetic reduction; ELISA, enzyme-linked immunosorbent assay.
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than 20 ng/mL. This means that it is highly sensitive (or low 
false negative) for assaying AFP. To demonstrate this point, 
six serum samples of early-stage HCC patients were used 
for the AFP assay with both ELISA and IMR, respectively. 
The results are shown in Figure 3. It was found that the three 
samples showed AFP concentrations lower than 20 ng/mL. 
This means that a high false negative exists. However, when 
using IMR, the detected AFP concentrations for these six 
serum samples were higher than 20 ng/mL. Moreover, all the 
six samples were positive according to the IMR results. Thus, 
the ultra-low detection threshold for assaying AFP achieved 
by IMR definitely suppresses the false negative.
The IMR (%) for AFP solutions without or with interfering 
materials were detected. The results are shown in   Figure 4A. 
The AFP concentration in each sample is 500 ng/mL. The 
pure AFP solution does not contain interfering material, and 
the label for interfering material is “None” for the pure AFP 
solution (Figure 4A). It is worth noting that all the samples 
exhibit IMR (%) around 2.27%. No definite deviations in 
IMR (%) were found among pure AFP solutions and those 
with interfering materials. Therefore, regardless of what 
materials were used, Hb, C-BL, TG, or VEGF, no detectable 
interference was shown for IMR assay on AFP.
The interference tests for AFP assay with ELISA were 
also investigated. The OD450 for each of the samples used in 
Figure 4A are shown in Figure 4B. For the pure AFP solution 
labeled with “None” in Figure 4B, the OD450 is 0.07 ± 0.003. 
However, for the AFP solution with interfering materials, 
the signals of OD450 are higher than 0.45. The results shown 
in Figure 4B reveal that materials such as Hb, C-BL, TG, 
and VEGF contribute a lot of interference to OD450 in the 
ELISA on AFP.
The nonsignificant interference from Hb, C-BL, TG, 
and VEGF for AFP assay with IMR is shown in Figure 4A. 
This evidence suggests that a high specificity could be 
achieved for assaying AFP with IMR. The interference for 
immunoassay is mainly attributed to sample color and cross 
reaction. The AFP solution with Hb/C-BL/TG is faintly 
red/orange/white. The sample color affects the emission/
transmission/absorption of fluorescent markers in ELISA. 
In addition, non-specific binding exists between antibod-
ies and nontarget molecules. Therefore, the OD450 of the 
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Figure 3 AFP concentration in sera of early-stage HCC patients detected by ELISA 
and IMR, respectively.
Note: Points represent mean ± standard deviation.
Abbreviations:  AFP,  alphafetaprotein;  HCC,  hepatocellular  carcinoma;  ELISA, 
enzyme-linked immunosorbent assay; IMR, hepatocellular carcinoma.
Figure 4 Contributions from various kinds of interfering materials to (A) IMR (%) 
and (B) OD450 measured with IMR and ELISA, respectively. The AFP concentration 
in each sample is 500 ng/mL.
Notes: The label “None” means there is no interfering material in the 500-ng/mL 
AFP solution; bars represent mean ± standard deviation.
Abbreviations:  AFP,  alphafetaprotein;  IMR,  immunomagnetic  reduction;  ELISA, 
enzyme-linked immunosorbent assay; OD, optical density; VEGF, vascular endothelial 
growth factor.
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AFP solution with interfering materials differs from that of 
the pure AFP solution. However, the signal detected with 
IMR is magnetic. The magnetic signals are transparent to 
any sample color. Hence, the sample color does not cause 
interference for IMR.
As for the nonspecific binding between the antibodies 
and nontarget molecules, it is significantly depressed with 
the centrifugal force acting on the nontarget molecules under 
ac magnetic fields. The detailed mechanism for the depres-
sion in the nonspecific binding for IMR has been clarified in 
a previous study.12 Briefly speaking, magnetic nanoparticles 
oscillate with the external ac magnetic fields when d  etecting 
the χac of the magnetic reagent. The nontarget molecules 
originally bound with antibodies on the oscillating mag-
netic nanoparticles experience centrifugal forces. At high 
oscillating frequencies, the centrifugal force is enhanced 
to break down the nonspecific binding. However, it is still 
weaker than the specific binding force between anti-AFP 
and AFP molecules. As a result, the cross reactions are 
inhibited for IMR.
Nineteen serum samples of patients with HCC are used 
for AFP assay via IMR. The results are shown with cross 
symbols (Figure 5). It was found that the AFP concentrations, 
φAFP , for these patients ranged from 19 to 100 ng/mL. As 
the AFP concentrations in the serum samples of 17 normal 
people were detected via IMR, it was found that the AFP 
concentrations were well below 15 ng/mL, as shown with 
dots (Figure 5). The preliminary results shown in Figure 5 
evidence the promising applications of IMR in diagnosing 
hepatocellular carcinoma.
Conclusion
In summary, it has been demonstrated that IMR shows 
the merits of a low detection threshold and nonsignificant 
  interference. The low detection threshold for assaying AFP is 
improved by 15 times by using IMR instead of ELISA. This 
ultra-low detection threshold definitely suppresses the false 
negative, which is usually found for ELISA, when assaying 
low-concentration AFP at early-stage HCC. It was proven that 
jaundice, hemolysis, or hypertriglyceridemia did not interfere 
with the detection of targeted molecules in blood by IMR. 
Furthermore, the clinic tests for ten samples of human blood 
using IMR evidence the high sensitivity and high specificity 
for assaying AFP with IMR. These results reveal the high 
feasibility for assaying AFP in blood with IMR.
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